// App-Quantinova.ai

602 : Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Dafna D Gladman

  • Eric K Davenport

  • Xiaolei Zhou

  • Benoit Guerette

  • Lichen Teng

  • Satyin Kaura

  • Peter Nash

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Krembil Research Institute, Toronto Western Hospital, Toronto, Canada

  • RTI Health Solutions, Research Triangle Park, NC

  • Celgene Corporation, Summit, NJ

  • The University of Queensland, Brisbane, Australia

Locations

  • United States

  • Canada

  • Australia

Companies

  • RTI Health Solutions

  • Celgene Corporation

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved